

Review Article

Bioactive dietary long-chain fatty acids: emerging mechanisms of action

Robert S. Chapkin^{1,2,3*}, David N. McMurray^{1,2,4}, Laurie A. Davidson^{1,2}, Bhimanagouda S. Patil^{1,3}, Yang-Yi Fan¹ and Joanne R. Lupton^{1,2}

¹Faculty of Nutrition, Texas A&M University, College Station, TX, USA

²Center for Environmental and Rural Health, Texas A&M University, College Station, TX, USA

³Vegetable and Fruit Improvement Center, Texas A&M University, College Station, TX, USA

⁴Department of Microbial and Molecular Pathogenesis, Texas A&M University Health Science Center, College Station, TX, USA

(Received 1 February 2008 – Revised 28 March 2008 – Accepted 31 March 2008 – First published online 20 May 2008)

The plasma membranes of all eukaryotic cells contain heterogeneous self-organising intrinsically unstable liquid ordered domains or lipid assemblies in which key signal transduction proteins are localised. These assemblies are classified as 'lipid rafts' (10–200 nm), which are composed mostly of cholesterol and sphingolipid microdomains and therefore do not integrate well into the fluid phospholipid bilayers. In addition, caveolae represent a subtype of lipid raft macrodomain that form flask-shaped membrane invaginations containing structural proteins, i.e. caveolins. With respect to the diverse biological effects of long-chain PUFA, increasing evidence suggests that *n*-3 PUFA and perhaps conjugated fatty acids uniquely alter the basic properties of cell membranes. Because of its polyunsaturation, DHA and possibly conjugated linoleic acid are sterically incompatible with sphingolipid and cholesterol and, therefore, appear to alter lipid raft behaviour and protein function. The present review examines the evidence indicating that dietary sources of *n*-3 PUFA can profoundly alter the biochemical make up of lipid rafts/caveolae microdomains, thereby influencing cell signalling, protein trafficking and cell cytokinetics.

Membrane rafts: *n*-3 Fatty acids: Conjugated fatty acids: Microdomains

The balance between cell proliferation and apoptosis is critical to the maintenance of steady-state cell populations in the body. In general, dysregulation of this mechanism can disrupt homeostasis, resulting in clonal expansion, with the resultant overproduction of affected cells. The programmed induction of cell death also represents a mechanism by which inappropriately activated cells and cells possessing DNA damage can be deleted. It has now been clearly established that chronic inflammation can perturb cellular homeostasis and drive malignant transformation by progressively inhibiting apoptosis of target cell types, for example, T-cells and epithelial cells^(1,2). Hence, chemotherapeutic agents such as dietary long-chain *n*-3 PUFA and possibly conjugated fatty acid species, which restore the normal proliferative and apoptotic pathways, have the potential for effectively treating cancers that depend on aberrations of these pathways to stay alive⁽³⁾. The following sections describe a mechanistic membrane-based model which may in part explain the pleiotropic properties of bioactive PUFA.

n-3 Polyunsaturated fatty acids

Although beyond the scope of the present review, a number of investigators have recently addressed the role of *n*-3 PUFA

in suppressing chronic inflammation and cancer^(4–6). With respect to mechanisms which functionally link the pleiotropic effects of bioactive dietary long-chain *n*-3 PUFA, inflammation and cancer, examples include (i) metabolic interconversion into novel bioactive eicosanoids^(7,8), (ii) modulation of nuclear receptor activation, gene transcription and translation^(9–12) (Fig. 1), (iii) alteration of membrane phospholipid composition and functionality of self-organising lipid domains⁽¹³⁾ (Fig. 2), (iv) effects on protein trafficking, including cytosol-to-membrane translocation^(4,14) and (v) interaction with SCFA to trigger lipid oxidation and intracellular Ca²⁺ compartmentalisation^(15,16).

The health benefits of long-chain PUFA are diverse and nutritional studies continue to demonstrate important benefits from the consumption of *n*-3 PUFA^(4,7,8,17–19). Since the use of a health claim on labels for foods containing *n*-3 PUFA has been approved, food companies are now mobilising to incorporate these fatty acids into a range of novel commercial foods in order to provide for the wider public consumption of these bioactive compounds. Hence, it is now important to precisely determine how specific long-chain PUFA modulate cell phenotype and reduce the risk of developing cancer and inflammatory disorders.

Abbreviation: CLA, conjugated linoleic acid.

* **Corresponding author:** Dr Robert S. Chapkin, fax +1 979 862 2378, email r-chapkin@tamu.edu




Fig. 1. Nuclear receptor activation by conjugated linoleic acid (CLA). FABP, fatty acid-binding proteins (molecular chaperone); ER, endoplasmic reticulum; RXR, retinoid X receptors. CLA transactivates PPAR nuclear receptors. *n*-3 PUFA suppress NF-κB activation. All membranes incorporate EPA, DHA and conjugated PUFA to different degrees.

Conjugated linoleic acid

There is growing interest with regard to the use and commercial availability of conjugated positional and geometric isomers of linoleic acid, particularly conjugated dienoic isomers of linoleic acid (conjugated linoleic acid; CLA). For example, in certain model systems, CLA is a powerful anti-cancer

agent, capable of promoting growth arrest and apoptosis in tumour cells^(20–22). In addition, CLA triggers adipose delipidation in rodent species^(23–25), and although there has been very little published clinical research^(26,27), recent preliminary evidence suggests that mixed-isomer CLA supplementation can alter fat oxidation and energy expenditure in human subjects^(28,29). However, the precise mechanism of action




Fig. 2. Putative membrane microdomain-altering properties of *n*-3 PUFA and conjugated linoleic acid (CLA). Dietary DHA and CLA are incorporated into both the bulk phase of the plasma membrane as well as discrete heterogeneous cholesterol/sphingolipid-rich raft domains. This can alter plasma membrane organisation of inner leaflets and the dynamic partitioning of transduction proteins, thereby modulating their function.

remains elusive. Since *n*-3 PUFA and CLA exhibit overlapping phenotypic properties, we propose a unifying molecular mechanism which may in part explain their protective effects.

Effect of bioactive polyunsaturated fatty acids on cell membranes

It is generally believed that the plasma membrane consists of a mosaic of functional microdomains that facilitate interactions between resident proteins and lipids^(30,31). Visible examples of these include caveolae, flask-shaped invaginations containing the structural protein caveolin-1 and many signal transduction proteins⁽³²⁾. In addition, morphologically heterogeneous featureless microdomains, consisting mostly of cholesterol and sphingolipids, unable to integrate well into the fluid phospholipid bilayers, exist as 'lipid rafts'⁽³³⁾. Although the existence of lipid rafts is still debated, new sophisticated imaging approaches have started to define cell surface nanoscale organisation⁽³¹⁾. Significantly, both cholesterol-dependent microdomains, analogous to lipid rafts, and non-raft signalling microdomains have been observed using electron microscopic imaging of two-dimensional plasma membrane sheets⁽³⁴⁾. These studies have provided a template for further investigation into the effects of dietary PUFA on cell surface organisation and cell cytokinetics, apoptosis and disease progression.

With respect to the biological effects of *n*-3 PUFA, increasing evidence suggests that DHA is a unique fatty acid because it significantly alters basic properties of cell membranes, including acyl (ester-linked fatty acid) chain order and fluidity, phase behaviour, elastic compressibility, ion permeability, fusion, rapid flip-flop and resident protein function⁽³⁵⁾. In part, due to the number of *cis* double bonds, DHA is sterically incompatible with sphingolipid and cholesterol and, therefore, appears to alter lipid raft behaviour⁽³⁵⁾. Interestingly, a number of studies have recently demonstrated that dietary *n*-3 PUFA are incorporated into diverse cell types and appear to uniquely modulate cell membrane microdomains^(13,36–39). Indeed, we recently demonstrated that *n*-3 PUFA feeding can markedly alter lipid/protein composition of mouse colonic caveolae microdomains, thereby selectively modulating the localisation and function of caveolar proteins^(13,14,37). In addition, we demonstrated that H-Ras and endothelial NO synthase are displaced from caveolae in *n*-3 PUFA-fed mice, which was associated with the suppression of Ras-dependent signalling. In contrast, localisation of non-caveolae-resident proteins, K-ras and clathrin, was not affected, indicating selective displacement of acylated signalling proteins from caveolae by *n*-3 PUFA. Our findings highlight a novel modality by which *n*-3 PUFA influence membrane micro-organisation, thereby modulating biological responses.

Using T-cell-culture models, Stulnig *et al.* were the first to document the ability of PUFA enrichment to selectively modify the cytoplasmic layer of lipid rafts^(40,41). In complementary experiments, we investigated the effect of dietary *n*-3 PUFA on cholesterol/sphingolipid-rich plasma membrane microdomains (i.e. rafts) in mouse splenic T-cells^(5,42,43). A very novel and unexpected outcome from this effort was the demonstration that dietary *n*-3 PUFA reduced (by about 45%) lipid raft sphingolipid content and altered raft fatty acid composition^(36,44,45). Therefore, we hypothesised that

PUFA classes (*n*-6 v. *n*-3) differentially modulate T-cell membrane microdomains, which is supported by recent studies indicating that stimulation-induced protein kinase C θ translocation into T-cell lipid rafts is suppressed by dietary *n*-3 PUFA⁽³⁶⁾. In addition, in an attempt to further probe the effects of DHA on protein kinase C θ effector pathway signalling, we have recently demonstrated that the diet modification of lipid rafts is associated with the suppression of transcription factor NF- κ B, AP-1 transcription site activation, IL-2 secretion and lymphoproliferation⁽³⁶⁾. With respect to lymphocyte subsets, recent studies indicate that the macromolecular complex organisation in lipid rafts is distinct in non-polarised, T helper cell, Th1 and Th2 polarised subsets⁽⁴⁶⁾. This would suggest that these subsets, i.e. regulators of cell-mediated immunity (Th1) and humoral immunity (Th2), would respond differently to dietary PUFA-induced perturbation. However, the ability of DHA to influence membrane raft-mediated signalling in polarised T-cells has not been determined to date.

There is cogent evidence indicating that lipid raft integrity is a prerequisite for optimised signalling between T-cells and antigen-presenting cells^(47,48). In addition, recent studies suggest that long-chain PUFA can block antigen presentation by interfering with lipid raft-dependent formation of the immunological synapse^(38,39,49). Overall, these findings provide evidence indicating that dietary *n*-3 PUFA can profoundly alter the biochemical make up of cell membrane lipid rafts/caveolae microdomains, which may directly or indirectly influence membrane fusion and cell–cell signalling. Interestingly, only a single study to date has examined the effects of CLA with regard to lipid raft/caveolae composition. Huot & Ma⁽⁵⁰⁾ demonstrated that mixed CLA isomers are concentrated in caveolae phospholipids, resulting in the reduction of caveolae-resident proteins, caveolin-1 and Her-2/neu, in Michigan Cancer Foundation (MCF)-7 breast cancer cells. Unfortunately, few studies to date have assessed the physical properties of CLA isomers⁽⁵¹⁾. Therefore, future studies using purified CLA isomers are needed in order to elucidate how conjugated fatty acid structure affects membrane structure and function.

Docosahexaenoic acid alters the size and distribution of lipid rafts

In a proof of principle study, we sought to determine the effect of DHA on the size and distribution of lipid rafts *in vivo*⁽¹⁷⁾. Using immunogold electron microscopy of plasma membrane sheets coupled with spatial point analysis, morphologically featureless microdomains were visualised in HeLa cells. Cells were transfected with green fluorescent protein truncated H-ras (GFP-tH), which is located exclusively to inner leaflet rafts, and subsequently incubated with DHA and control fatty acid, for example, oleic acid (18:1*n*-9) for 48 h. Univariate K-function analysis of GFP-tH (5 nm gold) revealed that the interparticle distance was significantly reduced by DHA treatment compared with control fatty acid, indicating that select PUFA can increase clustering of proteins in cholesterol-dependent microdomains (GFP-tH), whereas non-raft microdomains are insensitive to DHA modulation. These novel findings suggest that the plasma membrane organisation of inner leaflets is fundamentally altered by DHA enrichment (Fig. 2).

'Cholesterol-centric' view of membranes

SFA compared with PUFA have a preferential affinity for cholesterol. This relationship provides the basis for a lipid-driven mechanism for the lateral segregation of membrane elements into cholesterol-rich and -poor microdomains^(35,52–55). For example, unfavourable interaction between cholesterol and PUFA chains has been clearly demonstrated by the exclusion of cholesterol from dipolyunsaturated phosphatidylcholine membranes where it is forced to directly contact polyunsaturated chains. Studies using a variety of techniques including differential scanning calorimetry⁽⁵⁶⁾, ¹H NMR and nuclear Overhauser enhancement spectroscopy with magic angle spinning⁽⁵²⁾, determination of partition coefficients⁽⁵⁷⁾, measurements of lateral compressibility⁽⁵⁸⁾ and fluorescence anisotropy^(53,59) indicate that the poor affinity of DHA and perhaps CLA for cholesterol provides a lipid-driven mechanism for lateral phase separation of cholesterol-rich lipid microdomains from the surrounding bulk membrane. This could in principle alter the size, stability and distribution of cell surface lipid microdomains such as rafts. Indeed, growing evidence from model membrane studies suggest that the energetically less favourable interaction between cholesterol and PUFA, especially DHA, promotes lateral phase segregation into sterol-poor/PUFA-rich and sterol-rich/SFA-rich microdomains^(52,53,57,60–62).

Huang & Feigenson proposed the umbrella model to describe the solubility and condensing effect of cholesterol within membranes⁽⁶³⁾. According to this model, phospholipid head groups act as 'umbrellas' to prevent the energetically unfavourable contact of the non-polar part of cholesterol with interfacial water. This shielding will be less effective for DHA-containing phospholipids with a large molecular cross-sectional area, facilitating cholesterol precipitation at a lower concentration. In addition, this model allows for speculation that phosphatidylethanolamine with a smaller head group may enhance the DHA-associated reduction in shielding effects relative to phosphatidylcholine. Consistent with this notion, unlike phosphatidylcholine bilayers where a marked reduction in cholesterol solubility requires polyunsaturation at both *sn*-1 and *sn*-2 positions, DHA at the *sn*-2 position with a saturated *sn*-1 chain is sufficient in phosphatidylethanolamine to trigger cholesterol precipitation⁽⁶⁴⁾.

Conjugated *n*-3 polyunsaturated fatty acids

There is growing evidence that the combination of conjugated double bonds and *n*-3 PUFA may have enhanced chemoprotective properties. Recent studies using a number of model systems suggest that conjugated EPA and conjugated DHA suppress tumour growth^(65,66), suppress topoisomerases⁽⁶⁷⁾, induce apoptosis^(68,69), inhibit lipid accumulation⁽⁷⁰⁾ and have potential use as therapeutic dietary supplements for minimising tumour angiogenesis^(68,71). Typically, conjugated EPA and conjugated DHA are generated by alkaline isomerisation, producing a mixture of isomers with conjugated double bonds, although small amounts are found in marine algae and seal oil. Since the exact structure of these novel fatty acid species has not been fully characterised, future studies are required to verify their safety and efficacy in humans. In addition, it remains to be determined whether conjugated EPA and

conjugated DHA alter the size and distribution of cell surface microdomains.

Conclusion

A growing body of literature supports the contention that bioactive food components containing *n*-3 PUFA are important in suppressing chronic inflammation and cancer. Although the mechanism of EPA and DHA action is still not fully defined in molecular terms, it is becoming increasingly clear that *n*-3 PUFA alter cell membrane lipid microdomain composition, thereby favourably modulating the relay of extracellular signals from surface receptors to downstream signalling networks. Clearly, further studies are needed to clarify the nature of lipid rafts and the biological role of conjugated fatty acid species, including CLA, conjugated EPA and conjugated DHA families.

Acknowledgements

Financial support by National Institutes of Health grants CA59034, CA129444, DK071707 and P30ES09106, US Department of Agriculture 2005-34 402-16 401 Designing Foods for Health, and the American Institute for Cancer Research is gratefully acknowledged. There are no conflicts of interest associated with this manuscript. R. S. C., L. A. D., Y.-Y. F. and J. R. L. compiled data from collaborative experiments; D. N. M. evaluated the T-cell literature as well as contributions made from collaborative experiments. B. S. P. provided input related to novel fatty acid sources.

References

1. Karin M (2006) Nuclear factor- κ B in cancer development and progression. *Nature* **441**, 431–436.
2. Rollins BJ (2006) Inflammatory chemokines in cancer growth and progression. *Eur J Cancer* **42**, 760–767.
3. Hong MY, Lupton JR, Morris JS, Wang N, Carroll RJ, Davidson LA, Elder RH & Chapkin RS (2000) Dietary fish oil reduces O6-methylguanine DNA adduct levels in rat colon in part by increasing apoptosis during tumor initiation. *Cancer Epidemiol Biomarkers Prev* **9**, 819–826.
4. Chapkin RS, McMurray DN & Lupton JR (2007) Colon cancer, fatty acids and anti-inflammatory compounds. *Curr Opin Gastroenterol* **23**, 48–54.
5. Fowler KH, Chapkin RS & McMurray DN (1993) Effects of purified dietary *n*-3 ethyl esters on murine T-lymphocyte function. *J Immunol* **151**, 5186–5197.
6. Serhan CN, Yacoubian S & Yang R (2008) Anti-inflammatory and proresolving lipid mediators. *Annu Rev Pathol Mech Dis* **3**, 279–312.
7. Ariel A & Serhan CN (2007) Resolvins and protectins in the termination program of acute inflammation. *Trends Immunol* **28**, 176–183.
8. Bazan NG (2007) Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. *Curr Opin Clin Nutr Metab Care* **10**, 136–141.
9. deUrquiza AM, Liu S, Sjöberg M, Zetterström RH, Griffiths W, Sjövall J & Perlmann T (2000) Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. *Science* **290**, 2140–2144.

10. Fan YY, Spencer TE, Wang N, Moyer MP & Chapkin RS (2003) Chemopreventive *n*-3 fatty acids activate RXR α in colonocytes. *Carcinogenesis* **4**, 1541–1548.
11. Davidson LA, Nguyen DV, Hokanson RM, *et al.* (2004) Chemopreventive *n*-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. *Cancer Res* **64**, 6797–6804.
12. Jump DB, Botolin D, Wang Y, Xu J, Christian B & Demeure O (2005) Fatty acid regulation of hepatic gene transcription. *J Nutr* **135**, 2503–2506.
13. Ma DW, Seo J, Switzer KC, Fan YY, McMurray DN, Lupton JR & Chapkin RS (2004) *n*-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research. *J Nutr Biochem* **15**, 700–706.
14. Seo J, Barhoumi R, Johnson AE, Lupton JR & Chapkin RS (2006) Docosahexaenoic acid selectively inhibits plasma membrane targeting of lipidated proteins. *FASEB J* **20**, 770–772.
15. Kolar SS, Barhoumi R, Lupton JR & Chapkin RS (2007) Docosahexaenoic acid and butyrate synergistically induce colonocyte apoptosis by enhancing mitochondrial Ca²⁺ accumulation. *Cancer Res* **67**, 5561–5568.
16. Kolar SS, Barhoumi R, Callaway ES, Fan YY, Wang N, Lupton JR & Chapkin RS (2007) Synergy between docosahexaenoic acid and butyrate elicits p53-independent apoptosis via mitochondrial Ca²⁺ accumulation in colonocytes. *Am J Physiol Gastrointest Liver Physiol* **293**, G935–G943.
17. Chapkin RS, Wang N, Fan YY, Lupton JR & Prior IA (2008) Docosahexaenoic acid alters the size and distribution of cell surface microdomains. *Biochim Biophys Acta* **1778**, 466–471.
18. Biscione F, Pignalberi C, Totteri A, Messina F & Altamura G (2007) Cardiovascular effects of omega-3 free fatty acids. *Curr Vasc Pharmacol* **5**, 163–172.
19. Harris WS, Poston WC & Haddock CK (2007) Tissue *n*-3 and *n*-6 fatty acids and risk for coronary heart disease events. *Atherosclerosis* **193**, 1–10.
20. Ou L, Ip C, Lisafeld B & Ip MM (2007) Conjugated linoleic acid induces apoptosis of murine mammary tumor cells via Bcl-2 loss. *Biochem Biophys Res Commun* **356**, 1044–1049.
21. Bozzo F, Bocca C, Colombatto S & Miglietta A (2007) Antiproliferative effect of conjugated linoleic acid in Caco-2 cells: involvement of PPAR γ and APC/ β -catenin pathways. *Chem Biol Interact* **169**, 110–121.
22. Song HJ, Sneddon AA, Heys SD & Wahle KW (2006) Induction of apoptosis and inhibition of NF- κ B activation in human prostate cancer cells by the *cis*-9, *trans*-11 but not the *trans*-10, *cis*-12 isomer of conjugated linoleic acid. *Prostate* **66**, 839–846.
23. Chung S, Brown JM, Provo JN, Hopkins R & McIntosh MK (2005) Conjugated linoleic acid promotes human adipocyte insulin resistance through NF- κ B dependent cytokine production. *J Biol Chem* **280**, 38445–38456.
24. Liu LF, Purushotham A, Wendel AA & Belury MA (2007) Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice. *Am J Physiol Liver Physiol* **292**, G1671–G1682.
25. Pérez-Matute P, Marti A, Martínez JA, Fernández-Otero MP, Stanhope KL, Havel PJ & Moreno-Aliaga MJ (2007) Conjugated linoleic acid inhibits glucose metabolism, leptin and adiponectin-secretion in primary cultured rat adipocytes. *Mol Cell Endocrinol* **268**, 50–58.
26. Navarro V, Fernandez-Quintela A, Churrua I & Portillo MP (2006) The fat-lowering effect of conjugated linoleic acid: a comparison between animal and human studies. *J Physiol Biochem* **62**, 137–148.
27. Tricon S & Yaqoob P (2006) Conjugated linoleic acid and human health: a critical evaluation of the evidence. *Curr Opin Nutr Metab Care* **9**, 105–110.
28. Close RN, Schoeller DA, Watras AC & Nora EH (2007) Conjugated linoleic acid supplementation alters the 6-mo change in fat oxidation during sleep. *Am J Clin Nutr* **86**, 797–804.
29. Whigham LD, Watras AC & Schoeller DA (2007) Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. *Am J Clin Nutr* **85**, 1203–1211.
30. Laude AJ & Prior IA (2004) Plasma membrane microdomains: organization, function and trafficking. *Mol Membr Biol* **21**, 193–205.
31. Hancock JF (2006) Lipid rafts: contentious only from simplistic standpoints. *Nat Rev Mol Cell Biol* **7**, 456–462.
32. Anderson RGW (1998) The caveolae membrane system. *Annu Rev Biochem* **67**, 199–225.
33. Simons K & Ikonen E (1997) Functional rafts in cell membranes. *Nature* **387**, 569–572.
34. Prior IA, Muncke C, Parton RG & Hancock JF (2003) Direct visualization of Ras proteins in spatially distinct cell surface microdomains. *J Cell Biol* **160**, 165–170.
35. Stillwell W & Wassall SR (2003) Docosahexaenoic acid: membrane properties of a unique fatty acid. *Chem Phys Lipids* **126**, 1–27.
36. Fan YY, Ly LH, Barhoumi R, McMurray DN & Chapkin RS (2004) Dietary docosahexaenoic acid suppresses T-cell protein kinase C- θ lipid raft recruitment and interleukin-2 production. *J Immunol* **173**, 6151–6160.
37. Ma DW, Seo J, Davidson LA, Callaway ES, Fan YY, Lupton JR & Chapkin RS (2004) *n*-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon. *FASEB J* **18**, 1040–1042.
38. Zeyda M, Säemann MD, Stuhlmeier KM, Mascher DG, Nowotny PN, Zlabinger GJ, Waldhäusl W & Stulnig TM (2005) Polyunsaturated block dendritic cell activation and function independently of NF- κ B activation. *J Biol Chem* **280**, 14293–14301.
39. Geyeregger R, Zeyda M, Zlabinger GJ, Waldhäusl W & Stulnig TM (2005) Polyunsaturated fatty acids interfere with formation of the immunological synapse. *J Leuk Biol* **77**, 680–688.
40. Stulnig TM, Berger M, Sigmund T, Raederstorff D, Stockinger H & Waldhäusl W (1998) Polyunsaturated fatty acids inhibit T cell signal transduction by modification of detergent-insoluble membrane domains. *J Cell Biol* **143**, 637–644.
41. Stulnig TM, Huber J, Leitinger N, Imre E-M, Angelisová P, Nowotny P & Waldhäusl W (2001) Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. *J Biol Chem* **276**, 37335–37340.
42. Fowler KH, McMurray DN, Fan YY, Aukema HM & Chapkin RS (1993) Purified dietary *n*-3 polyunsaturated fatty acids alter diacylglycerol mass and molecular species composition in concanavalin A stimulated murine splenocytes. *Biochim Biophys Acta* **1210**, 89–96.
43. Switzer KC, McMurray DN, Morris JS & Chapkin RS (2003) Dietary *n*-3 polyunsaturated fatty acids selectively promote activation-induced cell death in T-lymphocytes. *J Nutr* **133**, 496–503.
44. Fan YY, McMurray DN, Ly LH & Chapkin RS (2003) Dietary (*n*-3) polyunsaturated fatty acids remodel mouse T-cell lipid rafts. *J Nutr* **133**, 1913–1920.
45. Switzer KC, Fan YY, Wang N, McMurray DM & Chapkin RS (2004) Dietary *n*-3 polyunsaturated fatty acids promote activation-induced cell death in the Th1-polarized murine CD4⁺T-cells. *J Lipid Res* **45**, 1482–1492.
46. Leitenberg D, Balamuth F & Bottomly K (2001) Changes in the T cell receptor macromolecular signaling complex and membrane microdomains during T cell development and activation. *Sem Immunol* **13**, 129–138.
47. Gaus K, Chklovskaja E, Fazekas de St Groth B, Jessup W & Harder T (2005) Condensation of the plasma membrane at the site of T lymphocyte activation. *J Cell Biol* **171**, 121–131.

48. Harder T, Rentero C, Zech T & Gaus K (2007) Plasma membrane segregation during T cell activation: probing the order of domains. *Curr Opin Immunol* **19**, 470–475.
49. Shaikh SR & Edidin M (2007) Immunosuppressive effects of polyunsaturated fatty acids on antigen presentation by human leukocyte antigen class I molecules. *J Lipid Res* **48**, 127–138.
50. Huot PS & Ma WL (2007) CLA incorporates into caveolae phospholipids and reduces caveolin-1 expression in MCF-7 cells. Presented at the 98th American Oil Chemists' Society (AOCS) Annual Meeting, Quebec, Canada, May 2007, p. 81. Urbana, IL: AOCS Press.
51. Yin JJ, Kramer JK, Yurawecz MP, Eynard AR, Mossoba MM & Yu L (2006) Effects of conjugated linoleic acid (CLA) isomers on oxygen diffusion-concentration products in liposomes and phospholipid solutions. *J Agric Food Chem* **54**, 7287–7293.
52. Huster D, Arnold K & Gawrisch K (1998) Influence of docosahexaenoic acid and cholesterol on lateral lipid organization in phospholipid mixtures. *Biochemistry* **37**, 17299–17308.
53. Mitchell DC & Litman BJ (1998) Effect of cholesterol on molecular order and dynamics in highly polyunsaturated phospholipid bilayers. *Biophys J* **75**, 896–908.
54. Pasenkiewicz-Gierula M, Subczynski WK & Kusumi A (1991) Influence of phospholipid unsaturation on the cholesterol distribution in membranes. *Biochimie* **73**, 1311–1316.
55. Niu SL & Litman BJ (2002) Determination of membrane cholesterol partition coefficient using a lipid vesicle-cyclodextrin binary system: effect of phospholipid acyl chain unsaturation and headgroup composition. *Biophys J* **83**, 3408–3415.
56. Zerouga M, Jensi LJ & Stillwell W (1995) Comparison of phosphatidylcholines containing one or two docosahexaenoic acyl chains on properties of phospholipid monolayers and bilayers. *Biochim Biophys Acta* **1236**, 266–272.
57. Kariel N, Davidson E & Keough KM (1991) Cholesterol does not remove the gel-liquid crystalline phase transition of phosphatidylcholines containing two polyenoic acyl chains. *Biochim Biophys Acta* **1062**, 70–76.
58. Needham D & Nunn RS (1990) Elastic deformation and failure of lipid bilayer membranes containing cholesterol. *Biophys J* **58**, 997–1009.
59. Mitchell DC & Litman BJ (1998) Molecular order and dynamics in bilayers consisting of highly polyunsaturated phospholipids. *Biophys J* **74**, 879–891.
60. Brzustowicz MR, Cherezov V, Caffrey M, Stillwell W & Wassall SR (2002) Molecular organization of cholesterol in polyunsaturated membranes: microdomain formation. *Biophys J* **82**, 285–298.
61. Brzustowicz MR, Cherezov V, Zerouga M, Caffrey M, Stillwell W & Wassall SR (2002) Controlling membrane cholesterol content. A role for polyunsaturated (docosahexaenoate) phospholipids. *Biochemistry* **41**, 12509–12519.
62. Pasenkiewicz-Gierula M, Subczynski WK & Kusumi A (1990) Rotational diffusion of a steroid molecule in phosphatidylcholine-cholesterol membranes: fluid-phase microimmiscibility in unsaturated phosphatidylcholine-cholesterol membranes. *Biochemistry* **29**, 4059–4069.
63. Huang J & Feigenson GW (1999) A microscopic interaction model of maximum solubility of cholesterol in lipid bilayers. *Biophys J* **76**, 2142–2157.
64. Shaikh SR, Cherezov V, Caffrey M, Stillwell W & Wassall SR (2003) Interaction of cholesterol with a docosahexaenoic acid-containing phosphatidylethanolamine: trigger for microdomain/raft formation? *Biochemistry* **42**, 12028–12037.
65. Danbara N, Yuri T, Tsujita-Kyutoku M, Sato M, Senzaki H, Takada H, Hada T, Miyazawa T, Okazaki K & Tsubura A (2004) Conjugated docosahexaenoic acid is a potent inducer of cell cycle arrest and apoptosis and inhibits growth of Colo 201 human colon cancer cells. *Nutr Cancer* **50**, 71–79.
66. Kimura Y & Sumiyoshi M (2005) Antitumor and antimetastatic actions of eicosapentaenoic acid ethylester and its by-products formed during accelerated stability testing. *Cancer Sci* **96**, 441–450.
67. Yonezawa Y, Tsuzuki T, Eitsuka T, *et al.* (2005) Inhibitory effect of conjugated eicosapentaenoic acid on human DNA topoisomerases I and II. *Arch Biochem Biophys* **435**, 197–206.
68. Tsuzuki T, Tanaka K, Kuwahara S & Miyazawa T (2005) Synthesis of the conjugated trienes 5E,7E,9E,14Z,17Z-eicosapentaenoic acid and 5Z,7E,9E,14Z,17Z-eicosapentaenoic acid and their induction of apoptosis in DLD-1 colorectal adenocarcinoma cells. *Lipids* **40**, 147–154.
69. Tsuzuki T, Kambe T, Shibata A, Kawakami Y, Nakagawa K & Miyazawa T (2007) Conjugated EPA activates mutant p53 via lipid peroxidation and induces p53-dependent apoptosis in DLD-1 colorectal adenocarcinoma human cells. *Biochim Biophys Acta* **1771**, 20–30.
70. Tsuzuki T, Kawakami Y, Nakagawa K & Miyazawa T (2006) Conjugated docosahexaenoic acid inhibits lipid accumulation in rats. *J Nutr Biochem* **17**, 518–524.
71. Tsuzuki T, Shibata A, Kawakami Y, Nakagawa K & Miyazawa T (2007) Anti-angiogenic effects of conjugated docosahexaenoic acid *in vitro* and *in vivo*. *Biosci Biotechnol Biochem* **71**, 1902–1910.